| SCA7 | |
|---|---|
| Full Name | ATXN7 (Ataxin-7) |
| Chromosomal Location | 3p12 |
| NCBI Gene ID | [6314](https://www.ncbi.nlm.nih.gov/gene/6314) |
| OMIM | [164500](https://www.omim.org/entry/164500) |
| UniProt ID | [Q9UQ50](https://www.uniprot.org/uniprotkb/Q9UQ50/entry) |
| Category | Transcription Factor |
| Protein Length | 892 amino acids |
| Inheritance | Autosomal dominant |
The SCA7 gene encodes ATXN7 (Ataxin-7), a transcriptional coactivator protein that plays a critical role in chromatin remodeling and gene expression regulation. SCA7 (Spinocerebellar Ataxia Type 7) is one of the polyglutamine (polyQ) expansion diseases, a group of nine autosomal dominant neurodegenerative disorders caused by CAG trinucleotide repeat expansions within the coding region of specific genes [1]. The expansion of a polyglutamine tract in the N-terminal region of ATXN7 leads to progressive neuronal dysfunction and death, primarily affecting the cerebellum and retina [2].
SCA7 is unique among polyglutamine diseases due to its combination of cerebellar ataxia and progressive visual loss from cone-rod dystrophy, a feature not seen in other ataxias [3]. The disease typically presents in the second to fourth decade of life, with earlier onset correlating with longer CAG repeat expansions [4].
The SCA7 gene (ATXN7) is located on chromosome 3p12 and consists of 13 exons spanning approximately 130 kb of genomic DNA [5]. The CAG repeat is located in exon 2, encoding a polyglutamine tract in the N-terminal region of the protein. Normal individuals carry 4-35 CAG repeats, while affected individuals have 36-130 repeats [4:1].
Recent research has identified multiple alternatively spliced isoforms of ATXN7 that generate pathogenic protein variants [6]. These isoforms differ in their N-terminal regions and demonstrate varying levels of toxicity in cellular models. The identification of these isoforms has important implications for therapeutic targeting, as some isoforms may be more amenable to splice-modulating therapies.
ATXN7 is a 892-amino acid protein with several distinct functional domains [7]:
ATXN7 is a core component of the SAGA (Spt-Ada-Gcn5 acetyltransferase) transcriptional coactivator complex [7:1]. The SAGA complex plays essential roles in:
The SAGA complex is evolutionarily conserved and regulates expression of genes involved in development, stress response, and cellular homeostasis [8].
In neurons, ATXN7 regulates expression of genes critical for cerebellar and retinal function [9]. Normal ATXN7 function includes:
The polyglutamine expansion in ATXN7 leads to a toxic gain-of-function [1:1]. The expanded polyQ tract undergoes conformational changes that result in:
The mutant ATXN7 protein disrupts normal transcriptional programs through multiple mechanisms [9:1]:
Patient-derived induced pluripotent stem cell (iPSC) models have demonstrated widespread transcriptional dysregulation, particularly affecting genes involved in mitochondrial function and oxidative stress response [10].
Multiple studies have demonstrated mitochondrial impairment in SCA7 [10:1]:
This mitochondrial dysfunction appears to be a central mechanism of neuronal death [11].
Like other polyglutamine diseases, SCA7 is characterized by neuronal intranuclear inclusions (NII) containing the mutant ATXN7 protein [3:1]. These aggregates:
The hallmark of SCA7 is progressive cerebellar ataxia [3:2]:
Pathological studies reveal:
SCA7 is unique among spinocerebellar ataxias for causing progressive visual loss [2:1]:
The retinal degeneration is thought to result from:
Several RNA-targeting approaches are in development [12]:
Viral vector-based approaches are being developed [13]:
Given the transcriptional dysregulation, epigenetic approaches are being explored [15]:
Targeting mitochondrial dysfunction is a promising approach [11:1]:
Promoting clearance of mutant protein through autophagy [16]:
Current clinical trial landscape for SCA7 [17]:
Several animal models have been developed:
These models have been instrumental in understanding disease mechanisms and testing therapeutic interventions.
ATXN7 interacts with several key protein complexes that are disrupted in SCA7:
The SAGA (Spt-Ada-Gcn5 acetyltransferase) complex is a multifunctional coactivator comprising multiple subunits that execute distinct enzymatic activities. ATXN7 serves as a critical bridge between the complex and transcription factors.
GCN5 (KAT2A): The catalytic subunit responsible for histone H3 acetyltransferase activity. GCN5-mediated acetylation of histone H3 at lysine 14 (H3K14ac) and lysine 9 (H3K9ac) is associated with transcriptional activation. In SCA7, mutant ATXN7 disrupts the proper recruitment of GCN5 to target gene promoters, leading to altered histone acetylation patterns and transcriptional dysregulation.
ADA2A/ADA2B: These adaptor proteins facilitate protein-protein interactions within the SAGA complex. They help position the GCN5 catalytic subunit and recruit transcriptional activators. Studies show that mutant ATXN7 can sequester ADA2A/B into aggregates, further compromising SAGA function.
SPT20 (SAGA-associated factor 20): A core SAGA component required for the integrity of the complex. SPT20 interactions with ATXN7 are disrupted by the polyglutamine expansion, affecting the structural stability of the SAGA complex.
USP22 (Ubiquitin-specific peptidase 22): The deubiquitinating enzyme component of SAGA. USP22 removes ubiquitin from histone H2B (H2Bub1) and other substrates. This activity is crucial for proper transcription elongation. In SCA7, USP22 function is impaired, leading to aberrant ubiquitination of chromatin substrates.
SGF29: A SAGA subunit that recognizes histone marks. The ATXN7-SGF29 interaction is important for targeting the SAGA complex to specific chromatin regions.
ATXN7 interacts with several transcription factors that are important for neuronal survival:
p53: The tumor suppressor protein p53 plays a dual role in SCA7. In its wild-type form, p53 can promote neuronal survival through transcriptional activation of pro-survival genes. However, mutant ATXN7 can alter p53 localization and function, potentially leading to apoptotic dysregulation.
CREB (cAMP response element-binding protein): A key transcription factor involved in learning and memory. CREB-mediated transcription is dysregulated in SCA7 models, contributing to synaptic dysfunction.
NF-κB: The nuclear factor kappa B signaling pathway is altered in SCA7. While NF-κB activation can be protective in some contexts, dysregulated NF-κB signaling contributes to neuroinflammation.
Nuclear receptors: ATXN7 interacts with various nuclear receptors including retinoic acid receptors (RARs) and thyroid hormone receptors. These interactions are important for neuronal differentiation and survival.
The cAMP/protein kinase A (PKA) signaling cascade is significantly altered in SCA7:
The mitogen-activated protein kinase (MAPK) pathway is affected:
The phosphatidylinositol 3-kinase (PI3K)/Akt survival pathway is compromised:
Calcium homeostasis is disrupted in SCA7:
The cellular protein quality control machinery is overwhelmed in SCA7:
SCA7 cells show increased sensitivity to DNA damage:
Lipid homeostasis is altered:
The cerebellum contains several cell types that are differentially vulnerable in SCA7:
Purkinje cells are the primary victims in SCA7:
Granule cells show secondary degeneration:
Inhibitory interneurons are affected:
The unique vulnerability of the retina in SCA7 involves:
Cone and rod photoreceptors show differential susceptibility:
Bipolar cells undergo secondary degeneration:
Retinal ganglion cells show late involvement:
Molecular diagnosis involves:
Several biomarkers are being investigated:
Neuroimaging reveals:
Several promising targets are under investigation:
Polyglutamine expansion diseases: future therapeutic strategies. Expert Opin Ther Targets. 2011. ↩︎ ↩︎
Retinal degeneration in spinocerebellar ataxia type 7. Ophthalmology. 2012. ↩︎ ↩︎
Cerebellar pathology in SCA7. Brain. 2017. ↩︎ ↩︎ ↩︎
Genotype-phenotype correlation in SCA7. Neurology. 2022. ↩︎ ↩︎
Molecular cloning of the SCA7 gene. Nat Genet. 1993. ↩︎
Alternative splicing of ATXN7 generates pathogenic isoforms. Brain. 2024. ↩︎
Ataxin-7 is a component of the SAGA transcriptional coactivator complex. J Biol Chem. 2006. ↩︎ ↩︎
SAGA complex in neurodegeneration. Trends Neurosci. 2018. ↩︎
Transcriptional dysregulation in polyglutamine diseases. Nat Rev Neurol. 2014. ↩︎ ↩︎
Patient-derived iPSC model of SCA7 reveals oxidative stress and mitochondrial dysfunction. Cell Stem Cell. 2015. ↩︎ ↩︎
Mitochondrial-targeted antioxidants for SCA7. Free Radic Biol Med. 2022. ↩︎ ↩︎
RNA-targeting therapies for SCA7. Nat Rev Neurol. 2021. ↩︎
Gene therapy approaches for SCA7. Mol Ther. 2024. ↩︎
CRISPR correction of SCA7 CAG repeat in patient cells. Nat Commun. 2020. ↩︎
Epigenetic therapy for polyglutamine diseases. Nat Rev Drug Discov. 2016. ↩︎
Autophagy induction for polyglutamine clearance. Autophagy. 2019. ↩︎
Clinical trials for SCA7: current status. Orphanet J Rare Dis. 2023. ↩︎